share_log

科兴制药(688136.SH)发布前三季度业绩,净利润1718万元,同比扭亏为盈

Kexing Biopharm (688136.SH) released its performance for the first three quarters, with a net income of 17.18 million yuan, turning losses into profits year-on-year.

Zhitong Finance ·  Oct 25 08:14

Kexing Biopharm (688136.SH) disclosed the third quarter report for 2024, achieving operating revenue for the first three quarters...

Zhixun Finance APP News, Kexing Biopharm (688136.SH) disclosed the third quarter report for 2024, achieving operating revenue of 1.038 billion yuan in the first three quarters, a year-on-year growth of 7.15%; net income attributable to the mother 17.18 million yuan, turning loss into profit year-on-year; non-net income 24.24 million yuan, turning loss into profit year-on-year; basic earnings per share 0.09 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment